Welcome!

@CloudExpo Authors: Zakia Bouachraoui, Elizabeth White, Liz McMillan, Pat Romanski, Roger Strukhoff

News Feed Item

Amarillo Biosciences Announces Open Enrollment in Its Phase 2 Study of Orally Administered Interferon Alpha in the Treatment of Oral Warts in HIV-Positive Patients

Amarillo Biosciences Announces Open Enrollment in Its Phase 2 Study of Orally Administered Interferon Alpha in the Treatment of

AMARILLO, TX -- (MARKET WIRE) -- 02/08/07 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that patients are now being enrolled in its FDA Phase 2 study testing low-dose interferon alpha lozenges administered orally to human immunodeficiency virus (HIV)-positive subjects with oral warts. Six clinical sites are participating in the study in San Francisco, Chicago, Boston, Dallas, Baltimore and New York City.

Viral lesions of the mouth in patients infected with HIV are common and may be indicative of disease progression. One of the causes of oral lesions is a group of DNA viruses, human papilloma viruses, which induce hyperplastic lesions in the oral soft tissue such as papillomas, warts, condylomata and focal epithelial hyperplasia.

Oral warts cause a significant reduction in quality of life due to their deleterious effects on patient appearance and potential for causing discomfort during routine activities such as eating and talking. Current treatment modalities include physical interventions such as cryosurgery, electrocoagulation, CO2 laser and excision; however, the rate of recurrence is high.

Two previous studies demonstrated the ability of interferon alpha lozenges to reduce oral wart load in HIV-positive patients. If, as anticipated, ABI's new study demonstrates the efficacy and safety of this treatment regimen, ABI intends to conduct a Phase 3 study before filing an NDA (New Drug Application), seeking marketing approval for interferon alpha lozenges in the treatment of oral warts in HIV-positive patients.

Clinical sites will enroll 80 patients in a study for which treatment will last 24 weeks. Interested patients are urged to contact Martin Cummins, Vice President, Clinical and Regulatory Affairs, via phone: 806-376-1741 ext. 14 or email: [email protected] for clinical site information.

The FDA's Office of Orphan Products Development has granted Orphan Drug Designation to ABI for natural human lymphoblastoid interferon-alpha in the treatment of papillomavirus warts in the oral cavity of HIV-positive patients.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13.5% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $37 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
E-mail: Email Contact
Tel: 800-477-7570
212-344-6464
Fax: 212-618-1276

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
E-mail: Email Contact
Tel: 806-376-1741 x 13
Fax: 806-376-9301

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

CloudEXPO Stories
The precious oil is extracted from the seeds of prickly pear cactus plant. After taking out the seeds from the fruits, they are adequately dried and then cold pressed to obtain the oil. Indeed, the prickly seed oil is quite expensive. Well, that is understandable when you consider the fact that the seeds are really tiny and each seed contain only about 5% of oil in it at most, plus the seeds are usually handpicked from the fruits. This means it will take tons of these seeds to produce just one bottle of the oil for commercial purpose. But from its medical properties to its culinary importance, skin lightening, moisturizing, and protection abilities, down to its extraordinary hair care properties, prickly seed oil has got lots of excellent rewards for anyone who pays the price.
The platform combines the strengths of Singtel's extensive, intelligent network capabilities with Microsoft's cloud expertise to create a unique solution that sets new standards for IoT applications," said Mr Diomedes Kastanis, Head of IoT at Singtel. "Our solution provides speed, transparency and flexibility, paving the way for a more pervasive use of IoT to accelerate enterprises' digitalisation efforts. AI-powered intelligent connectivity over Microsoft Azure will be the fastest connected path for IoT innovators to scale globally, and the smartest path to cross-device synergy in an instrumented, connected world.
There are many examples of disruption in consumer space – Uber disrupting the cab industry, Airbnb disrupting the hospitality industry and so on; but have you wondered who is disrupting support and operations? AISERA helps make businesses and customers successful by offering consumer-like user experience for support and operations. We have built the world’s first AI-driven IT / HR / Cloud / Customer Support and Operations solution.
ScaleMP is presenting at CloudEXPO 2019, held June 24-26 in Santa Clara, and we’d love to see you there. At the conference, we’ll demonstrate how ScaleMP is solving one of the most vexing challenges for cloud — memory cost and limit of scale — and how our innovative vSMP MemoryONE solution provides affordable larger server memory for the private and public cloud. Please visit us at Booth No. 519 to connect with our experts and learn more about vSMP MemoryONE and how it is already serving some of the world’s largest data centers. Click here to schedule a meeting with our experts and executives.
Darktrace is the world's leading AI company for cyber security. Created by mathematicians from the University of Cambridge, Darktrace's Enterprise Immune System is the first non-consumer application of machine learning to work at scale, across all network types, from physical, virtualized, and cloud, through to IoT and industrial control systems. Installed as a self-configuring cyber defense platform, Darktrace continuously learns what is ‘normal' for all devices and users, updating its understanding as the environment changes.